Chai Discovery key facts
as of Oct 2026- Developer of an AI-based molecular interactions platform designed for molecular structure prediction that performs state-of-the-art across tasks relevant to drug discovery.
- Chai Discovery is valued at approximately $1.3B as of Oct 2026 (last reported valuation).
- It has raised $230.0M across 4 recorded rounds; the latest was Series C ($400.0M) in Jul 2026.
- Notable investors include General Catalyst, SV Angel, AWS Startups, Menlo Ventures, DCVC — 21 tracked in total.
- Status: Privately Held (backing).
Chai Discovery's last reported valuation, Dec 2025. Nothing priced has surfaced since.
- ·The complete investor list: 21 names
- ·Watch Chai Discovery: the Monday email on marks, rounds and moves
Chai Discovery funding rounds
4 roundsChai Discovery leadership
- Joshua MeierCo-Founder & CEO
- Jack DentCo-Founder & President
- Matt McPartlonCo-Founder
- Jacques BoitreaudCo-Founder
Who backs Chai Discovery
21+Membership and data by Private Market View
Chai Discovery valuation
Chai Discovery's last reported valuation was $1.3 billion in Dec 2025. No priced round, secondary trade or fund mark has surfaced since.
How much has Chai Discovery raised?
Chai Discovery has raised $230 million across 4 recorded rounds since 2024. The largest was a $70 million Series A in Aug 2025; the most recent was a $400 million Series C in Jul 2026.
Chai Discovery investors
21 investors are on record for Chai Discovery, including General Catalyst, SV Angel, AWS Startups and Menlo Ventures. By type, the record holds 11 venture capital firms and 2 growth equity firms.
Who runs Chai Discovery
4 people are listed on the Chai Discovery team: 4 executives, including Jack Dent (Co-Founder) and Jacques Boitreaud (Co-Founder).
Comparable companies
Comparable biotech names by valuation on PrivateMarketView: Xaira Therapeutics ($3.5 billion), InSilico Medicine Cayman (HKG: 03696) ($1.7 billion) and Merida Biosciences ($228 million).
About Chai Discovery
Developer of an AI-based molecular interactions platform designed for molecular structure prediction that performs state-of-the-art across tasks relevant to drug discovery. The company's platform operates models that can predict the structure of biochemical molecules and reprogram how they interact for developing new medications, enabling researchers to get unified predictions of proteins, small molecules, DNA, RNA, and covalent modifications.
- Industry
- Biotech
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 28
- Website
- chaidiscovery.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.